TY - JOUR
T1 - Long-standing and poorly controlled disease in juvenile dermatomyositis is associated with calcinosis
T2 - a real-world experience from a low-middle income country
AU - Mehta, Pankti
AU - Lawrence, Able
AU - Gupta, Latika
AU - Misra, Durga P
AU - Agarwal, Vikas
AU - Misra, Ramnath
AU - Aggarwal, Amita
N1 - © 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
PY - 2023/7/5
Y1 - 2023/7/5
N2 - To study the prevalence and predictors of calcinosis in Juvenile Dermatomyositis (JDM). Medical records over 20 years at a tertiary care rheumatology center in Northern India were reviewed to identify patients with JDM and clinical details were recorded. The frequency of calcinosis, predictors, specific treatment, and its outcomes were studied. Data are expressed as median and interquartile range. In eighty-six patients (median age 10) of JDM, the frequency of calcinosis was 18.2% (8.5% at presentation). Younger age at presentation, longer follow-up, heliotrope rash [Odds Ratio (95% confidence interval), 11.4 (1.4-92.12)], chronic or polycyclic course [4.4 (1.2-15.5)] and cyclophosphamide use [8.2 (1.6-41.9)] were associated with calcinosis. Dysphagia [0.14 (0.02-1.2)] and elevated muscle enzymes [0.14 (0.04-0.5)] were negatively associated with calcinosis. Treatment with pamidronate had a good to moderate response to calcinosis in five of seven children. Calcinosis in JDM is associated with long-standing, poorly controlled disease, and the use of bisphosphonates like pamidronate offer promise in the future for its treatment.
AB - To study the prevalence and predictors of calcinosis in Juvenile Dermatomyositis (JDM). Medical records over 20 years at a tertiary care rheumatology center in Northern India were reviewed to identify patients with JDM and clinical details were recorded. The frequency of calcinosis, predictors, specific treatment, and its outcomes were studied. Data are expressed as median and interquartile range. In eighty-six patients (median age 10) of JDM, the frequency of calcinosis was 18.2% (8.5% at presentation). Younger age at presentation, longer follow-up, heliotrope rash [Odds Ratio (95% confidence interval), 11.4 (1.4-92.12)], chronic or polycyclic course [4.4 (1.2-15.5)] and cyclophosphamide use [8.2 (1.6-41.9)] were associated with calcinosis. Dysphagia [0.14 (0.02-1.2)] and elevated muscle enzymes [0.14 (0.04-0.5)] were negatively associated with calcinosis. Treatment with pamidronate had a good to moderate response to calcinosis in five of seven children. Calcinosis in JDM is associated with long-standing, poorly controlled disease, and the use of bisphosphonates like pamidronate offer promise in the future for its treatment.
KW - Calcinosis
KW - Cyclophosphamide
KW - Dermatomyositis
KW - Pamidronate
KW - Rheumatology
UR - http://www.scopus.com/inward/record.url?scp=85164514685&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/a761fe4e-41ef-3484-b900-48677489060c/
U2 - 10.1007/s00296-023-05377-4
DO - 10.1007/s00296-023-05377-4
M3 - Article
C2 - 37405442
SN - 0172-8172
JO - Rheumatology International
JF - Rheumatology International
ER -